Blog

American Bitcoin expected to trade on Nasdaq under the ticker symbol “ABTC”

MIAMI, FL and LAS VEGAS, NV / ACCESS Newswire / July 1, 2025 / American Bitcoin Corp. (“American Bitcoin” or the “Company”), a Bitcoin accumulation platform focused on building America’s Bitcoin infrastructure backbone, and Gryphon Digital Mining, Inc. (Nasdaq:GRYP) (“Gryphon”), an innovative venture in the Bitcoin mining space, today announced the filing of an amended registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with their previously announced stock-for-stock merger transaction (the “Transaction”).

The Registration Statement, which amends the initial version filed in June, contains a preliminary proxy statement and prospectus in connection with the proposed Transaction. While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about American Bitcoin, Gryphon, and the Transaction.

American Bitcoin has entered into a definitive merger agreement with Gryphon pursuant to which Gryphon will acquire American Bitcoin in a stock-for-stock merger transaction. Upon closing, the combined company will operate under the American Bitcoin brand, led by the management and board of directors of American Bitcoin. The combined company is expected to trade on Nasdaq under the ticker symbol “ABTC,” with the Transaction targeted to close as early as Q3 2025.

Additional Information

A copy of the amended Registration Statement filed by Gryphon with the SEC is available here.

About American Bitcoin

American Bitcoin is a majority-owned subsidiary of Hut 8 focused exclusively on industrial-scale Bitcoin mining and strategic Bitcoin reserve development. The company combines Hut 8’s proven mining operations, cost-efficient infrastructure development capabilities, and disciplined approach to capital allocation with Eric Trump’s commercial acumen, capital markets expertise, and commitment to the advancement of decentralized financial systems. For more information, visit www.americanbtc.com and follow us on X at @AmericanBTC.

About Gryphon

Gryphon Digital Mining, Inc. is an innovative venture in the Bitcoin mining space. More information is available on www.gryphondigitalmining.com.

Cautionary Note Regarding Forward-Looking Information

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 175 promulgated thereunder, and Section 21E of the Securities Exchange Act of 1934, as amended, and Rule 3b-6 promulgated thereunder, which statements involve inherent risks and uncertainties. Examples of forward-looking statements, include, but are not limited to, statements relating to the structure, timing, and completion of the proposed transaction between American Bitcoin and Gryphon, the combined company’s listing on Nasdaq after the closing of the proposed transaction, the expected management and board of directors of the combined company, and the vision, goals, and trajectory of American Bitcoin and the combined company.

Forward-looking statements are not statements of historical fact, but instead represent management’s expectations, estimates, and projections regarding future events based on certain material factors and assumptions at the time the statement was made. While considered reasonable by American Bitcoin as of the date of this press release, such statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking statements, including, but not limited to: the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the merger agreement; the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Gryphon’s stockholders, if at all; risks related to Gryphon’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that may be instituted against American Bitcoin, Gryphon, or the combined company; the possibility that the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the integration of the two companies may be more difficult, time-consuming or costly than expected; the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events; the diversion of management’s attention from ongoing business operations and opportunities; changes in Gryphon’s stock price before closing; and other factors that may affect future results of American Bitcoin, Gryphon, or the combined company. Additional factors that could cause results to differ materially from those described above can be found in Gryphon’s most recent annual report on Form 10-K for the fiscal year ended December 31, 2024 and other documents subsequently filed by Gryphon with the SEC.

Additional Information About the Proposed Transaction and Where to Find It

This press release relates to a proposed transaction between American Bitcoin and Gryphon. In connection with the proposed transaction, Gryphon has filed with the SEC a Registration Statement to register the Class A common stock to be issued by Gryphon in connection with the proposed transaction. The Registration Statement includes a proxy statement of Gryphon and a prospectus of Gryphon (the “Proxy Statement/Prospectus”), and each of American Bitcoin and Gryphon may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Gryphon to seek their approval of the proposed transaction. This press release is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that American Bitcoin or Gryphon has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF GRYPHON ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AMERICAN BITCOIN, GRYPHON, THE PROPOSED TRANSACTION, AND RELATED MATTERS.

Participants in the Solicitation

American Bitcoin, Gryphon and certain of their respective directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Gryphon, their ownership of Gryphon common stock, and Gryphon’s transactions with related persons is set forth in its Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 31, 2025, the definitive proxy statement for Gryphon’s 2024 annual meeting of stockholders, as filed with the SEC on August 7, 2024, the definitive proxy statement for Gryphon’s 2025 special meeting of stockholders, as filed with the SEC on April 21, 2025, and other documents that may be filed from time to time with the SEC. Additional information about the directors and executive officers of American Bitcoin and Gryphon and other persons who may be deemed to be participants in the solicitation of stockholders of Gryphon in connection with the proposed transaction and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will be filed with the SEC. These documents may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov and from Gryphon using the sources indicated above.

No Offer or Solicitation

This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.

American Bitcoin Corp. Investor Relations
ir@americanbtc.com

American Bitcoin Corp. Public Relations
media@americanbtc.com

SOURCE: Gryphon Digital Mining, Inc.

View the original press release on ACCESS Newswire

LAS VEGAS, NV / ACCESS Newswire / July 1, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) (“ALT5 or the “Company”), a fintech company providing blockchain-powered payment and trading infrastructure for global merchants and financial institutions, has announced today that it has been added as a member of the Russell Microcap Growth^®, Russell 3000E^® and Russell 3000E Growth^® Indexes, as part of the 2025 Russell indexes reconstitution. The Company had previously been included in the Russel Microcap^® Index since June of 2024.

“The recent reconstitution of the Russell indexes and our inclusion in both the Russell 3000E and Russell 3000E Growth Indexes is a powerful validation of our sustained momentum and strengthening fundamentals,” said Peter Tassiopoulos, CEO of ALT5 Sigma Corporation. “This recognition reflects the market’s growing confidence in our strategic vision, execution capabilities, and long-term value creation for stockholders. We are honored to be part of these prestigious benchmarks and see it as a catalyst for increased visibility and institutional interest moving forward.”

FTSE Russell determines index membership primarily based on objective market capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. As of June 28, 2024, Russell’s U.S. indexes served as the benchmark for approximately $10.6 trillion in assets. Russell indexes are part of FTSE Russell, a global index provider.

Peter Tassiopoulos went on to comment “Today’s announcement builds on ALT5’s position as a leading provider of blockchain-based payment and trading infrastructure. Founded in 2018, the Company supports over 1,000 businesses globally and has processed more than $5 billion USD in cryptocurrency transactions since inception, underscoring its role as a trusted partner to institutions and merchants operating in the digital asset economy.”

Fiona Bassett, CEO of FTSE Russell, An LSEG business, comments:

“The Russell indexes have continuously adapted to the evolving dynamic US economy, and it’s crucial to fully recalibrate the suite of Russell US Indexes, ensuring the indexes maintain an accurate representation of the market. The transition to a semi-annual reconstitution frequency from 2026 will ensure our indexes continue to represent the market and maintain the purpose of the index as a portfolio benchmark.”

For more information on the Russell Microcap^® Index and the Russell indexes reconstitution, visit the “Russell Reconstitution” section on the FTSE Russell website.

About ALT5 Sigma Corporation
ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. the Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index

Founded in 2018, ALT5 Sigma, Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: “ALT5 Pay” and “ALT5 Prime.” The company has processed over $5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

The Company is also advancing the separation of its biotech business, which will continue under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

About FTSE Russell, an LSEG Business
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit FTSE Russell.

Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5’s platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion. This press release also may contain statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company‘s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the sections entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media/Investor Relations Contact
IR@alt5sigma.com
1-800-400-2247

SOURCE: ALT5 Sigma Corp

View the original press release on ACCESS Newswire

MCLEAN, VA / ACCESS Newswire / July 1, 2025 / Gladstone Alternative Income Fund (“Gladstone Alternative” or the “Fund”) announced today that its board of trustees declared monthly cash distributions to shareholders for the month of July, increasing the daily dividend rate by greater than 1.1%, in comparison to the June daily dividend rate. The July distribution amount is $0.00178 per calendar day for each issued and outstanding Class A share, Class C share, and Class I share for the period beginning July 1, 2025 and ending July 31, 2025 (for shareholders who own shares all 31 days in July, the distribution will total approximately $0.0552 per share). The distributions will be paid on July 31, 2025 for Dividend Reinvestment Plan (“DRIP”) participants and August 1, 2025 for non-DRIP participants.

John Sateri, President of Gladstone Alternative, noted, “We are pleased to announce the fifth consecutive monthly dividend for Gladstone Alternative, continuing our commitment to delivering consistent income to our investors. We look forward to continuing to create long-term value in the months and years ahead by generating sustainable returns for our shareholders while providing them access to a diversified portfolio of private credit and equity investments.”

About Gladstone Alternative Income Fund

Gladstone Alternative Income Fund is a non-diversified, unlisted, closed-end management investment company registered under the Investment Company Act of 1940 and is operating as an interval fund. The Fund seeks to achieve and grow current income by investing primarily in directly originated loans to lower and middle market private businesses in the United States, broadly syndicated loans and commercial real estate loans.

Investors are advised to carefully consider the investment objectives, risks and charges, and expenses of Gladstone Alternative Income Fund before investing. The prospectus, dated November 7, 2024, which has been filed with the U.S. Securities and Exchange Commission, and as supplemented from time to time, contains this and other information about the Fund and should be read carefully before investing. You may get these documents for free by visiting the Fund’s website at www.gladstoneintervalfund.com or by visiting EDGAR on the SEC’s website at www.sec.gov. To obtain a copy of the prospectus, you may also contact Gladstone Securities, LLC, the dealer manager and distributor for this offering, which will arrange to send you the prospectus if you request it by calling toll-free at (833) 849-5993.

For further information, please visit our website at www.gladstoneintervalfund.com.

SOURCE: Gladstone Alternative Income Fund

View the original press release on ACCESS Newswire

For New York homeowners facing foreclosure, a powerful legal reform is shifting the balance. The Foreclosure Abuse Prevention Act (“FAPA”), signed into law in December 2022, has introduced substantial new protections that limit abusive litigation practices by lenders. But many consumers are still asking: What does FAPA stand for-and how does it work?

NEW YORK CITY, NY / ACCESS Newswire / July 1, 2025 / Petroff Amshen LLP, a law firm focused on consumer protection and foreclosure defense, is shedding light on the scope and impact of FAPA in New York, and how it is already helping homeowners regain leverage in long-running foreclosure cases.

What Does FAPA Stand For?

FAPA stands for the Foreclosure Abuse Prevention Act-a state law designed to end lender tactics that exploit procedural loopholes to restart or extend foreclosure cases indefinitely.

Before FAPA, banks and mortgage servicers could manipulate the timeline of a foreclosure by voluntarily pausing and re-filing cases, effectively resetting the statute of limitations. This left many homeowners in limbo, facing lawsuits years after they believed the matter was resolved or abandoned.

Now, under FAPA New York, this kind of procedural abuse is no longer allowed. The law restores fairness and finality to the foreclosure process by:

• Clarifying how and when the six-year statute of limitations is triggered

• Preventing lenders from revoking their decision to accelerate a mortgage simply to extend the time to sue

• Limiting the ability to refile foreclosure actions on the same default

• Reversing and codifying prior decisions from the New York Court of Appeals into state law

Why FAPA Matters for Homeowners

The passage of FAPA has immediate implications for thousands of New York homeowners who are either in foreclosure or at risk. For many, the law may mean a foreclosure action is now time-barred, making it subject to dismissal under New York’s six-year limit on mortgage enforcement.

“FAPA was passed because the system was being abused-and homeowners were paying the price,” said Steven Amshen, Founding Partner of Petroff Amshen LLP. “This law is about restoring balance and giving families a real defense against endless litigation.”

How Petroff Amshen LLP Uses FAPA to Defend Homeowners

Petroff Amshen LLP has already leveraged FAPA in active foreclosure litigation, helping clients challenge cases that exceed the statute of limitations. Their approach includes:

• Reviewing the entire history of the foreclosure process to identify timeline violations

• Challenging lenders’ claims when deadlines have expired

• Filing motions to dismiss cases under FAPA grounds

• Pursuing broader legal relief where appropriate, including cancellation of mortgages through Article 15 actions

The firm represents clients across New York who have been entangled in foreclosure actions for years-many of whom were previously told there was no legal path forward.

Know Your Rights Under FAPA – New York

If you’re currently facing foreclosure or have been re-sued on a mortgage years after the first filing, you may have legal grounds for dismissal. FAPA in New York may apply even if previous cases were discontinued or dismissed.

Petroff Amshen LLP urges homeowners to have their cases reviewed by attorneys who understand this law and its power to stop wrongful foreclosure actions.

Stay Informed. Stay Protected. Stay Connected.

Petroff Amshen LLP shares legal updates, court decisions, and consumer-focused resources to help New Yorkers protect their homes. With nearly two decades of experience in foreclosure defense, the firm continues to lead in applying new laws like FAPA for the benefit of everyday homeowners.

Follow Petroff Amshen LLP for updates on FAPA and foreclosure defense:

Instagram: @petroffamshen

Facebook: Petroff Amshen LLP

LinkedIn: Petroff Amshen LLP | New York

Contact Information

Gabriel Botero
Media Relations
media@petroffamshen.com
(718) 336-4200

SOURCE: Petroff Amshen LLP

View the original press release on ACCESS Newswire

Next‑Gen Amnio-Chorionic Membrane for Enhanced Wound Care is Latest Offering in a Slew of New Products Focused on Increasing Patient Care

LAS VEGAS, NV / ACCESS Newswire / July 1, 2025 / New Horizon Medical Solutions, a leader in advanced biologics and wound care innovation, today announced the launch and addition of AmchoPlast™ to its product portfolio. AmchoPlast is a premium amniotic‑chorionic membrane (amnion – chorion with intermediate layer) product designed to elevate outcomes across surgical and chronic wound indications.

“AmchoPlast strengthens our pipeline of compliant, performance-driven biologics that align with modern wound care protocols,” said Will Hall, CEO, New Horizon Medical Solutions. “This launch reflects our commitment to regenerative medicine, practice optimization, and elevating standards of care.”

Delivering superior benefits and practice optimization

• Engineered with amiotic-chorionic tissue, AmchoPlast serves as a natural biologic scaffold and barrier, supporting advanced wound care management.

• Biocompatible and non-immunogenic, the membrane is safe for a diverse patient population and a wide range of wound types.

• Tri-layer construction provides enhanced handling properties and slower degradation compared to single or bi-layer membranes

Designed for clinical workflow and reimbursement ease

• Supplied in a sterile, ready-to-use format, AmchoPlast cuts procedural prep time and minimizes infection risk.

• Shelf-stable at room temperature, it supports versatile storage for hospitals, clinics, or mobile settings.

• Flexible, easy-to-handle, and available in multiple sizes, it facilitates precise application and reduces product wastage.

“The addition of AmchoPlast cements our portfolio as the most complete in the biologics space,” said D. Christopher Keil, SVP, strategy & corporate development. “We now offer providers and partners the broadest range of choices when selecting regenerative solutions from New Horizon.”

About AmchoPlast™

AmchoPlast, from Cellution Biologics, combines the power of amniotic and chorionic tissues with intermediate layer in a tri-layered construct. Intended to act as a barrier and provide protective coverage from the surrounding environment for acute and chronic wounds such as partial and full thickness wounds, pressure sores/ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (e.g., donor site/grafts, post-laser surgery, post-Mohs surgery, podiatric wounds, wound dehiscence), trauma wounds (e.g., abrasions, lacerations, partial thickness burns, skin tears), and draining wounds. For more information on the product, visit nhmedical.com/products/amchoplast or contact New Horizon Medical Solutions directly at 702-960-2913.

About New Horizon Medical Solutions

New Horizon Medical Solutions is at the forefront of biologic innovation and practice optimization. The company develops regenerative tissue products supported by reimbursement expertise and operational efficiency, empowering providers to improve patient outcomes while maintaining compliance. www.nhmedical.com

—
Media Contact

Julian Rogers, Director of Corporate Marketing
New Horizon Medical Solutions
julian.rogers@nhmedical.com
702-971‑1806

SOURCE: New Horizon Medical Solutions

View the original press release on ACCESS Newswire

Designed for real-life mobility, the Toyota Sienna Hybrid FlexMaxx™ offers families and individuals a quiet, fuel-efficient and adaptable solution for everyday travel.

RICHFIELD, OH / ACCESS Newswire / July 1, 2025 / MobilityWorks, the nation’s largest provider of wheelchair accessible vehicles, mobility equipment, and services, is proud to announce the launch of the Toyota Sienna Hybrid FlexMaxx™ Rear-Entry conversion, available exclusively through MobilityWorks locations nationwide beginning July 1, 2025.

Developed by Driverge Vehicle Innovations, this rear-entry conversion offers the unmatched reliability of Toyota’s hybrid platform – delivering up to 36 MPG – combined with the proven flexibility and performance of Driverge’s FlexMaxx™ design. With a unique seating system that allows for second-row or third-row wheelchair transport, the vehicle can be easily reconfigured to accommodate changing passenger needs-whether it’s one wheelchair user and up to four passengers, or full seating for ambulatory travel.

“This exclusive offering brings together two things our clients care deeply about: cutting-edge automotive technology and flexible, accessible design,” said Chris Paczak, Chief Marketing and Merchandising Officer of MobilityWorks. “The Toyota Hybrid FlexMaxx™ is more than just a wheelchair accessible vehicle, it’s engineered to combine Toyota’s hybrid system and Driverge’s Quiet Ride™ technology together to help families ‘Be There’ like no other wheelchair accessible vehicle ever has. Driverge Vehicle Innovations has been able to maintain the OEM vehicle aesthetic on the front and sides of the van, while engineering a 36-inch wide wheelchair ramp that can be opened and closed using one finger with Driverge’s spring assist system. There is nothing on the market today like this accessible vehicle.”

Key Features of the FlexMaxx™ Rear-Entry Toyota Sienna Hybrid:

• Flexible Seating Configurations: Accommodates up to 4 passengers + 1 wheelchair user

• 2nd-Row Flip-and-Fold Seating: Quick conversion between passenger and wheelchair transport while maintaining OEM aesthetic

• Extra-Wide 36″ Manual Ramp: Designed for ease and versatility, the rear-entry ramp is wide enough to accommodate a range of mobility devices, is spring-assisted and lightweight for ease of use

• OEM-Level Design Aesthetic: Maintains the original Toyota Sienna look on the front and sides for a sleek, factory-finished appearance, blending accessibility with modern design

• Hybrid Performance: Fuel-efficient Toyota technology meets accessibility without compromise and retains the OEM fuel tank

• Quiet Ride™ Technology: Designed with Driverge’s proprietary Quiet Ride™ system for a smoother, quieter experience inside the cabin

• Exclusive Availability: Only available for purchase at MobilityWorks locations in the U.S.

With NMEDA MQAP certification and design approved by the National Highway Traffic Safety Administration, the FlexMaxx™ is ideal for both personal and family use, offering a seamless blend of quality, comfort, and confidence.

Clients can begin placing orders for the new vehicle starting July 1 at any MobilityWorks location or by calling 877-275-4907.

About MobilityWorks:

MobilityWorks is the nation’s largest retailer of wheelchair accessible vehicles, mobility equipment and services. MobilityWorks is a portfolio company of Flexpoint Ford, a private equity firm that specializes in investments in the healthcare and financial services industries. MobilityWorks Commercial is the largest provider of commercial wheelchair vans in the country. MobilityWorks and manufacturer Driverge Vehicle Innovations together make up WMK, LLC, established in 1997 and recognized on the Inc. 500|5000 list of Inc. Magazine’s fastest-growing privately held companies, as well as Newsweek’s list of America’s Greatest Workplaces.

Contact Information

Kelly Stobie
Internal Communications & PR Manager
kelly.stobie@mobilityworks.com
234-200-1381

SOURCE: MobilityWorks

View the original press release on ACCESS Newswire

Next‑Gen Amnio-Chorionic Membrane for Enhanced Wound Care is Latest Offering in a Slew of New Products Focused on Increasing Patient Care

LAS VEGAS, NV / ACCESS Newswire / July 1, 2025 / New Horizon Medical Solutions, a leader in advanced biologics and wound care innovation, today announced the launch and addition of AmchoPlast™ to its product portfolio. AmchoPlast is a premium amniotic‑chorionic membrane product designed to elevate outcomes across surgical and chronic wound indications.

“AmchoPlast strengthens our pipeline of compliant, performance-driven biologics that align with modern wound care protocols,” said Will Hall, CEO, New Horizon Medical Solutions. “This launch reflects our commitment to regenerative medicine, practice optimization, and elevating standards of care.”

Delivering superior benefits and practice optimization

• Engineered with amniotic‑chorionic tissue, AmchoPlast serves as a natural biologic scaffold and barrier, supporting advanced wound care management and regenerative tissue growth.

• Rich in growth factors and cytokines, it enhances angiogenesis, reduces inflammation, and promotes cellular proliferation and differentiation.

• Biocompatible and non-immunogenic, the membrane is safe for a diverse patient population and a wide range of wound types.

• With anti-inflammatory and anti-fibrotic activity, AmchoPlast helps reduce scarring, minimize adhesions, and accelerates epithelialization.

Designed for clinical workflow and reimbursement ease

• Supplied in a sterile, ready-to-use format, AmchoPlast cuts procedural prep time and minimizes infection risk.

• Shelf-stable at room temperature, it supports versatile storage for hospitals, clinics, or mobile settings.

• Flexible, easy-to-handle, and available in multiple sizes, it facilitates precise application and reduces product wastage.

• Supported by HCPCS‑compliant Q codes, AmchoPlast streamlines billing and reimbursement in line with CMS and payer requirements.

“The addition of AmchoPlast cements our portfolio as the most complete in the biologics space,” said D. Christopher Keil, SVP, strategy & corporate development. “We now offer providers and partners the broadest range of choices when selecting regenerative solutions from New Horizon.”

About AmchoPlast™

AmchoPlast, from Cellution Biologics, combines the regenerative power of amniotic and chorionic tissues in a dual-layer membrane. Intended for surgical reconstruction, chronic wounds (including diabetic foot ulcers and pressure injuries), burns, tendon and nerve repair, the product supports homologous use in clinical application, wound care, and optimized patient outcomes. For more information on the product, visit nhmedical.com/products/amchoplast or contact New Horizon Medical Solutions directly at 702-960-2913.

About New Horizon Medical Solutions

New Horizon Medical Solutions is at the forefront of biologic innovation and practice optimization. The company develops regenerative tissue products supported by reimbursement expertise and operational efficiency, empowering providers to improve patient outcomes while maintaining compliance. www.nhmedical.com
—
Media Contact
Julian Rogers, Director of Corporate Marketing
New Horizon Medical Solutions
julian.rogers@nhmedical.com
702-971‑1806

SOURCE: New Horizon Medical Solutions

View the original press release on ACCESS Newswire

• Backed by over two years of development and 500+ global institutional clients, VelaFi enters the market with mature infrastructure and proven scale.
• With operations across LATAM, the U.S., Asia, and expanding into EMEA, VelaFi delivers modern infrastructure for businesses navigating complex financial environments.

MEXICO CITY, MEXICO AND DALLAS, TX / ACCESS Newswire / July 1, 2025 / After over two years of development and operations, Galactic Holdings, the parent company of TruBit Business, officially announces the launch of VelaFi: the natural evolution of its enterprise-focused vertical. This new identity reflects a more focused, institutional, and global vision, built on a foundation of solid technology and hands-on experience.

With over 500 institutional global clients and a validated infrastructure, VelaFi positions itself as a mature platform built to operate across complex and fragmented financial environments. The company currently has active operations in Latin America, the United States, Hong Kong, and Singapore, and continues to expand partnerships across the Middle East, Europe, and Africa.

VelaFi’s launch comes at a pivotal moment for the transformation of the global financial system. Stablecoins have now surpassed $250 billion in circulation worldwide, signaling increasing and sustained market adoption. As regulatory frameworks around digital payments continue to evolve businesses operating across jurisdictions require modern, reliable infrastructure aligned with new compliance expectations.

“We’ve spent years building the infrastructure that businesses in emerging markets actually need,” said Maggie Wu, CEO and Co-Founder of VelaFi. “This isn’t about entering the market-we’ve been here, solving real problems for real companies. What you’re seeing now is the natural evolution of that work: proven technology, established relationships, and a clear vision for how cross-border financial infrastructure should work in today’s economy.”

VelaFi was born from a deep understanding of the challenges that companies face in emerging markets. From its early days as TruBit Business, the company identified a critical need: financial infrastructure capable of navigating fragmented regulatory environments, inconsistent banking relationships, and cross-border operational demands, without sacrificing speed or compliance.

That vision has been shaped through direct experience with clients in sectors like import/export, logistics, SaaS, fintech, and global services. Through these partnerships, the platform has evolved into a model that not only processes transactions but also delivers operational tools, regional intelligence, and a regulatory-first architecture ready to scale.

The name VelaFi, inspired by the Spanish word vela (sail), reflects the company’s philosophy: direction, structure, and the ability to move forward, even in turbulent waters. Today, the platform offers scalable payment solutions, integrable APIs, and real-time tools for treasury management, reconciliation, and compliance, all built with regulatory readiness at its core.

This foundation has proven its ability to scale sustainably, not just through geographic reach, but by adapting to diverse environments, integrating with local systems, and providing structure where the market often delivers uncertainty. VelaFi doesn’t aim to impose a one-size-fits-all model, it builds from the logic of each market, using strong infrastructure principles as the basis for global growth.

“Our clients don’t need another payment processor,” Wu added. “They need infrastructure that understands the complexity of their operations and provides clarity where the market only offers fragmentation. That’s what we’ve built-and that’s what we’re scaling.”

In a world where companies increasingly operate across multiple currencies, jurisdictions, and regulatory frameworks, VelaFi addresses a structural challenge: enabling sustainable growth through modern, intelligent infrastructure. With a clear institutional focus and a proven platform, the company is entering a new phase of expansion-launching new products and deepening its international presence to support businesses operating across the world’s most complex markets.

About VelaFi
VelaFi is a financial infrastructure platform designed for companies operating in emerging markets and fragmented financial environments. Evolved from TruBit Business – the B2B unit of Galactic Holdings – it provides cross-border payment solutions, regulatory compliance tools, and operational scalability for institutions.

The platform currently operates across Latin America, the United States, and Asia, with expansion underway into the Middle East, Europe, and Africa. Its mission is clear: to build the infrastructure layer that real companies need to grow without friction in a transforming financial system.

Press contact: roberto.femat@velafi.com

For more information, visit www.velafi.com

SOURCE: Galactic Holdings

View the original press release on ACCESS Newswire

Hwang to Lead Next Phase of Growth as Long-Time CEO Austin Vanchieri Becomes Executive Chair

NORTH CANTON, OHIO / ACCESS Newswire / July 1, 2025 / Visual Edge IT, Inc., a national leader in managed IT services and office technology solutions, today announced the appointment of James Hwang as Chief Executive Officer, effective July 7, 2025. Hwang will also join the company’s Board of Directors. He succeeds Austin Vanchieri, who will transition to the role of Executive Chair of the Board of Directors after more than three decades of executive leadership. Vanchieri will continue to provide strategic leadership in his role of Executive Chair.

Hwang brings to Visual Edge IT a distinguished track record of operational excellence and transformational leadership in the IT services sector. He most recently served as CEO of 1Path Holdings, a comprehensive IT services and consulting firm based in Atlanta. Prior to that, Hwang led Cal Net Technology Group, one of the foundational companies that became the nationwide IT managed services platform known as NexusTek. Under his leadership, Cal Net was honored as Channel Futures’ MSP of the Year.

“It has been an incredible honor to lead Visual Edge IT for more than 31 years,” said Austin Vanchieri. “Our team has built a resilient and innovative organization that now spans more than 70 markets across the U.S. and with James’ experience and leadership, I’m confident Visual Edge is well-positioned to be a leader in the next era of industry growth and technology innovation.”

“I am excited and honored to join Visual Edge IT at such an important moment in its journey,” said Hwang. “I look forward to working with our employees, customers, and partners to accelerate innovation, enhance value, and expand our national reach.”

The appointment marks a pivotal milestone in Visual Edge IT’s ongoing transformation into a comprehensive national technology solutions provider. Hwang’s leadership will focus on scaling service offerings, deepening customer relationships, and driving growth across both IT services and office technology platforms.

About Visual Edge IT, Inc.

Visual Edge IT is a national provider of managed IT services, cybersecurity, and office technology solutions. With a network of over 70 service locations across the U.S., Visual Edge IT delivers best-in-class technology solutions designed to improve efficiency, security, and business performance for small and midsize businesses nationwide.

https://visualedgeit.com/blog/visual-edge-it-appoints-james-hwang-as-chief-executive-officer

SOURCE: Visual Edge IT, Inc.

Related Images

View the original press release on ACCESS Newswire